Looking up for Canadian device review times
This article was originally published in Clinica
Executive Summary
With a few exceptions, Canadian review times for class II, III and IV medical devices are improving. Figures for January-march 2001 published by MEDEC, the national medical device industry association (Toronto) showed that class II review time were within the 15-day limit and class III times exceeded the 75-day limit by 11 days. Only in the class IV highest risk category was there anything negative to report, the 75-day limit being exceeded by 71 days.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.